The percentage of the central memory T cells in mice treated with FeMOF-based cancer vaccines, such as CD44highCD62Lhigh in CD4+ T cells, is much higher than that those treated with saline or free dLLC autologous tumor antigens (Figure 7). This evidence concerns the gene CD4 and neoplasm.